Precigen (PGEN) Non-Current Deferred Tax Liability (2015 - 2024)
Precigen's (PGEN) quarterly Non-Current Deferred Tax Liability came in at $1.3 million in Q4 2024, down 88.39% year-on-year from $10.9 million in Q1 2024, and up 1328.09% on a QoQ basis from $89000.0 in Q3 2024.
Precigen (PGEN) Non-Current Deferred Tax Liability (2015 - 2024) Analysis & Trends
Precigen (PGEN) has 10 years of Non-Current Deferred Tax Liability data on file, last reported at $1.3 million in Q4 2024.
- On a quarterly basis, Non-Current Deferred Tax Liability fell 88.39% year-over-year to $1.3 million in Q4 2024; TTM through Dec 2024 was $1.3 million, a 88.39% decrease from a year earlier, with the FY2024 full-year figure at $1.3 million, down 88.39% from the prior year.
- Non-Current Deferred Tax Liability for Q4 2024 stood at $1.3 million, up from $89000.0 in the prior quarter.
- Over the last five years, Non-Current Deferred Tax Liability for PGEN reached as high as $18.5 million in Q4 2021 and fell as low as $77000.0 in Q2 2024.
- Historically, Non-Current Deferred Tax Liability has averaged $3.9 million across 5 years, with a median of $2.4 million in 2022.
- Across the five-year window, Non-Current Deferred Tax Liability surged 383.69% in 2023 and slumped 96.47% in 2024, its largest moves.
- Year by year, Non-Current Deferred Tax Liability stood at $12.6 million in 2020, then soared by 47.0% to $18.5 million in 2021, then sank by 87.8% to $2.3 million in 2022, then jumped by 383.69% to $10.9 million in 2023, then plunged by 88.39% to $1.3 million in 2024.
- Per Business Quant data, the three most recent Non-Current Deferred Tax Liability figures were $1.3 million in Q4 2024, $89000.0 in Q3 2024, and $77000.0 in Q2 2024.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - |
| 10 | Precigen | 1.96 Bn | 1.96 Bn | 20.69 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 1.27 Mn |
| Dec 31, 2024 | 1.27 Mn |
| Sep 30, 2024 | 89,000.00 |
| Sep 30, 2024 | 89,000.00 |
| Jun 30, 2024 | 77,000.00 |
| Jun 30, 2024 | 77,000.00 |
| Mar 31, 2024 | 1.78 Mn |
| Mar 31, 2024 | 1.78 Mn |
| Dec 31, 2023 | 10.95 Mn |
| Dec 31, 2023 | 10.95 Mn |
| Sep 30, 2023 | 2.13 Mn |
| Sep 30, 2023 | 2.13 Mn |
| Jun 30, 2023 | 2.18 Mn |
| Jun 30, 2023 | 2.18 Mn |
| Mar 31, 2023 | 2.24 Mn |
| Mar 31, 2023 | 2.24 Mn |
| Dec 31, 2022 | 2.26 Mn |
| Dec 31, 2022 | 2.26 Mn |
| Sep 30, 2022 | 2.09 Mn |
| Sep 30, 2022 | 2.09 Mn |